NextCure Inc
NXTC11.380USD
+0.680+6.36%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
30.45MMarket Cap
LossP/E TTM
More Details of NextCure Inc Company
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
NextCure Inc Info
Ticker SymbolNXTC
Company nameNextCure Inc
IPO dateMay 09, 2019
CEORichman (Michael S)
Number of employees43
Security typeOrdinary Share
Fiscal year-endMay 09
Address9000 Virginia Manor Rd Ste 200
CityBELTSVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20705-4214
Phone12403994900
Websitehttps://www.nextcure.com/
Ticker SymbolNXTC
IPO dateMay 09, 2019
CEORichman (Michael S)
Company Executives of NextCure Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Richman
Mr. Michael Richman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
34.69K
+2.46%
Dr. David S. Kabakoff, Ph.D.
Dr. David S. Kabakoff, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.19K
--
Dr. Udayan Guha, M.D., J.D.
Dr. Udayan Guha, M.D., J.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Independent Director
Independent Director
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin G. Shaw, J.D.
Mr. Kevin G. Shaw, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Dr. Timothy Mayer, Ph.D.
Dr. Timothy Mayer, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Sourav Kundu, Ph.D.
Dr. Sourav Kundu, Ph.D.
Senior Vice President - Development and Manufacturing
Senior Vice President - Development and Manufacturing
--
--
Mr. Stephen W. Webster
Mr. Stephen W. Webster
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Richman
Mr. Michael Richman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
34.69K
+2.46%
Dr. David S. Kabakoff, Ph.D.
Dr. David S. Kabakoff, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.19K
--
Dr. Udayan Guha, M.D., J.D.
Dr. Udayan Guha, M.D., J.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Independent Director
Independent Director
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Simcere Zaiming, Inc
12.64%
Sofinnova Investments, Inc
8.31%
Affinity Asset Advisors LLC
7.16%
Squadron Capital Management LLC
6.49%
Pfizer Inc
5.88%
Other
59.52%
Shareholders
Shareholders
Proportion
Simcere Zaiming, Inc
12.64%
Sofinnova Investments, Inc
8.31%
Affinity Asset Advisors LLC
7.16%
Squadron Capital Management LLC
6.49%
Pfizer Inc
5.88%
Other
59.52%
Shareholder Types
Shareholders
Proportion
Corporation
18.52%
Investment Advisor
11.34%
Hedge Fund
8.63%
Venture Capital
8.31%
Investment Advisor/Hedge Fund
4.57%
Individual Investor
1.65%
Other
46.99%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
82
863.97K
32.24%
-615.29K
2025Q2
90
1.31M
49.01%
-420.40K
2025Q1
93
15.91M
56.72%
-4.70M
2024Q4
99
16.68M
59.57%
-2.91M
2024Q3
113
18.48M
66.07%
-4.88M
2024Q2
115
18.65M
66.68%
-4.54M
2024Q1
124
18.78M
67.32%
-1.96M
2023Q4
131
15.99M
57.34%
-5.33M
2023Q3
145
15.65M
56.21%
-6.81M
2023Q2
152
15.96M
57.33%
-6.41M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Simcere Zaiming, Inc
338.64K
12.65%
+338.64K
--
Jul 14, 2025
Sofinnova Investments, Inc
222.66K
8.32%
--
--
Jun 30, 2025
Affinity Asset Advisors LLC
191.88K
7.17%
--
--
Jun 30, 2025
Pfizer Inc
13.14K
0.49%
-151.09K
-92.00%
Jun 30, 2025
The Vanguard Group, Inc.
72.67K
2.72%
-9.61K
-11.68%
Jun 30, 2025
Cable Car Capital LLC
63.18K
2.36%
+7.34K
+13.14%
Jun 30, 2025
Acadian Asset Management LLC
40.70K
1.52%
--
--
Jun 30, 2025
Richman (Michael S)
34.69K
1.3%
+834.00
+2.46%
Apr 23, 2025
Renaissance Technologies LLC
41.74K
1.56%
+1.75K
+4.37%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 10, 2025
Merger
12→1
Date
Type
Ratio
Jul 10, 2025
Merger
12→1
FAQs
Who are the top five shareholders of NextCure Inc?
The top five shareholders of NextCure Inc are:
Simcere Zaiming, Inc holds 338.64K shares, accounting for 12.65% of the total shares.
Sofinnova Investments, Inc holds 222.66K shares, accounting for 8.32% of the total shares.
Affinity Asset Advisors LLC holds 191.88K shares, accounting for 7.17% of the total shares.
Pfizer Inc holds 13.14K shares, accounting for 0.49% of the total shares.
The Vanguard Group, Inc. holds 72.67K shares, accounting for 2.72% of the total shares.
Simcere Zaiming, Inc holds 338.64K shares, accounting for 12.65% of the total shares.
Sofinnova Investments, Inc holds 222.66K shares, accounting for 8.32% of the total shares.
Affinity Asset Advisors LLC holds 191.88K shares, accounting for 7.17% of the total shares.
Pfizer Inc holds 13.14K shares, accounting for 0.49% of the total shares.
The Vanguard Group, Inc. holds 72.67K shares, accounting for 2.72% of the total shares.
What are the top three shareholder types of NextCure Inc?
The top three shareholder types of NextCure Inc are:
Simcere Zaiming, Inc
Sofinnova Investments, Inc
Affinity Asset Advisors LLC
Simcere Zaiming, Inc
Sofinnova Investments, Inc
Affinity Asset Advisors LLC
How many institutions hold shares of NextCure Inc (NXTC)?
As of 2025Q3, 82 institutions hold shares of NextCure Inc, with a combined market value of approximately 863.97K, accounting for 32.24% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -16.77%.
What is the biggest source of revenue for NextCure Inc?
In FY2021, the -- business generated the highest revenue for NextCure Inc, amounting to -- and accounting for --% of total revenue.
